Abstract：
UNASSIGNED: Many studies have discussed the betahistine treatment for Meniere\'s disease (MD). However, regarding cochlear MD, there is no consensus on the long-term betahistine treatment.
UNASSIGNED: This study aims to investigate the relationship between the betahistine treatment duration in patients with cochlear MD and their clinical outcomes.
UNASSIGNED: We enrolled 78 patients with 96 ears who were diagnosed with cochlear MD and received the treatment for more than 6 months. Outcomes included the hearing status, frequency of acute hearing loss attack, and whether the disease progressed to MD. Clinical characteristics including age, sex, side of affected ear, treatment duration of betahistine and trichlormethiazide, and pre-treatment hearing level was recorded from medical charts.
UNASSIGNED: Comparing the clinical characteristics by outcomes, the average betahistine treatment duration was the independent factor for hearing status of four-tone average (p = 0.01) and low-tone average (p = 0.03). Patients with average betahistine treatment duration of at least 277 days per year had higher odds ratio for improvement of the hearing status of four-tone and low-tone average.
UNASSIGNED: For patients with cochlear MD, regular and long-term betahistine treatment can benefit their hearing outcome in the low- and medium-frequency.
UNASSIGNED: This study aims to investigate the relationship between the betahistine treatment duration in patients with cochlear MD and their clinical outcomes.
UNASSIGNED: We enrolled 78 patients with 96 ears who were diagnosed with cochlear MD and received the treatment for more than 6 months. Outcomes included the hearing status, frequency of acute hearing loss attack, and whether the disease progressed to MD. Clinical characteristics including age, sex, side of affected ear, treatment duration of betahistine and trichlormethiazide, and pre-treatment hearing level was recorded from medical charts.
UNASSIGNED: Comparing the clinical characteristics by outcomes, the average betahistine treatment duration was the independent factor for hearing status of four-tone average (p = 0.01) and low-tone average (p = 0.03). Patients with average betahistine treatment duration of at least 277 days per year had higher odds ratio for improvement of the hearing status of four-tone and low-tone average.
UNASSIGNED: For patients with cochlear MD, regular and long-term betahistine treatment can benefit their hearing outcome in the low- and medium-frequency.
摘要：
■许多研究讨论了倍他司汀治疗梅尼埃病（MD）的方法。然而,关于耳蜗MD，对倍他司汀的长期治疗尚无共识.
■本研究旨在探讨耳蜗MD患者的倍他司汀治疗持续时间与临床结局之间的关系。
■我们招募了78例96耳患者，这些患者被诊断为耳蜗MD，并接受了超过6个月的治疗。结果包括听证状态，急性听力损失发作的频率，以及疾病是否进展为MD。临床特征包括年龄,性别,受影响的耳朵一侧，倍他司汀和三氯噻嗪的治疗持续时间，治疗前的听力水平是从医学图表中记录的。
■根据结果比较临床特征，平均倍他司汀治疗持续时间是四音调平均(p=0.01)和低音调平均(p=0.03)听力状态的独立因素.平均倍他司汀治疗时间为每年至少277天的患者在改善四音和低音平均听力状态方面的优势比较高。
■对于患有耳蜗MD的患者，定期和长期的倍他司汀治疗可以使他们的低频和中频听力结果受益。
■本研究旨在探讨耳蜗MD患者的倍他司汀治疗持续时间与临床结局之间的关系。
■我们招募了78例96耳患者，这些患者被诊断为耳蜗MD，并接受了超过6个月的治疗。结果包括听证状态，急性听力损失发作的频率，以及疾病是否进展为MD。临床特征包括年龄,性别,受影响的耳朵一侧，倍他司汀和三氯噻嗪的治疗持续时间，治疗前的听力水平是从医学图表中记录的。
■根据结果比较临床特征，平均倍他司汀治疗持续时间是四音调平均(p=0.01)和低音调平均(p=0.03)听力状态的独立因素.平均倍他司汀治疗时间为每年至少277天的患者在改善四音和低音平均听力状态方面的优势比较高。
■对于患有耳蜗MD的患者，定期和长期的倍他司汀治疗可以使他们的低频和中频听力结果受益。
